The Valley Desk

ArticleDermatology and therapyPublished

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Dermatology and therapy
Published
Subject terms
Cytokine; Pharmacodynamics; Psoriasis; Tyrosine Kinase 2; Deucravacitinib
PubMed ID
39283417
PubMed Central ID
PMC11480296
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal